Evidence map›Paper›PMID 42380677›Full record

ArticleNature medicine2026

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.

Stephanie Gomez, Rachel A DiCioccio, Ashley E Geiger, Melanie L Grant, Emily Reynolds, Anushree Datar, Chase D McCann, Jay Tanna, Divyesh Kukadiya, Fahmida Hoq and 12 more

Erratum issuedAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Stephanie Gomez *Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-4494-659X
Rachel A DiCioccio *Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-5551-527X
Ashley E GeigerChildren's National Hospital, Washington, DC, USA.
Melanie L GrantEmory University School of Medicine, Atlanta, GA, USA.
Emily ReynoldsChildren's National Hospital, Washington, DC, USA.
Anushree DatarChildren's National Hospital, Washington, DC, USA.
Chase D McCannChildren's National Hospital, Washington, DC, USA.
Jay TannaChildren's National Hospital, Washington, DC, USA.
Divyesh KukadiyaChildren's National Hospital, Washington, DC, USA.
Fahmida HoqChildren's National Hospital, Washington, DC, USA.
Anqing ZhangChildren's National Hospital, Washington, DC, USA.
Patrick J HanleyChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-0102-7892
Jennifer L WebbChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0003-1463-4963
Lindsay B KilburnChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0003-1478-3619
Brian R RoodChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0003-3221-9421
Adriana FonsecaChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-6382-6833
Holly J MeanyChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-2230-8351
L Gilbert VézinaChildren's National Hospital, Washington, DC, USA.
Roger J PackerChildren's National Hospital, Washington, DC, USA.
Conrad Russell Y CruzChildren's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-7065-3769
Catherine M BollardChildren's National Hospital, Washington, DC, USA. cbollard@childrensnational.org.ORCID http://orcid.org/0000-0001-5140-9090
Eugene I HwangChildren's National Hospital, Washington, DC, USA. ehwang@childrensnational.org.ORCID http://orcid.org/0000-0002-3923-1135

Funding

NextGen - CRIOT2CA278700 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI Catherine M. Bollard · 2022 to 2026
$5.6M
Cancer Biology Training Program (CBTP)T32CA247756 · NCI · GEORGE WASHINGTON UNIVERSITY · PI LEE, NORMAN H, SETO, EDWARD · 2020 to 2024
$1.4M
NCI NIH HHS OT2 CA278700NCI NIH HHS T32 CA247756
6 · The paper itself

Abstract

Central nervous system (CNS) tumors are the deadliest cancers in children, highlighting the need for new therapies. The tumor-associated antigens (TAAs) WT1, PRAME and survivin are widely expressed by these tumors, and a manufacturing technique has been developed to target these intracellular TAAs using autologous, nongenetically engineered T cells. Here we therefore conducted ReMIND, an open-label, phase 1 adaptive dose-finding study to determine the safety/feasibility of autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin in children with CNS tumors. Eligible patients had newly diagnosed diffuse intrinsic pontine glioma without lymphodepletion (arm A, n = 16 enrolled, n = 11 infused) and relapsed/recurrent nonbrainstem CNS malignancies without (arm B, n = 28 enrolled, n = 18 infused) or with (arm C, n = 7 enrolled, n = 4 infused) lymphodepletion. Primary end points were safety, feasibility and maximum tolerated dose determination; secondary end points included preliminary efficacy and immunobiological correlates, including in vivo TAA-T persistence and systemic immune activation. Dose level 3 (8 × 10

Indexed as

Antigens, NeoplasmCentral Nervous System NeoplasmsDiffuse Intrinsic Pontine GliomaT-LymphocytesAdolescentChildChild, PreschoolFemaleHumansMaleMaximum Tolerated DoseSurvivinWT1 ProteinsAntigens, NeoplasmBIRC5 protein, humanSurvivinWT1 Proteins

Identifiers

PMID42380677
PMCPMC13375545

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.